Guardant Health’s (GH) “Overweight” Rating Reaffirmed at Stephens

Guardant Health (NASDAQ:GH)‘s stock had its “overweight” rating reissued by investment analysts at Stephens in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $55.00 price objective on the stock. Stephens’ price objective would indicate a potential upside of 21.82% from the company’s current price.

A number of other brokerages also recently weighed in on GH. Barclays assumed coverage on Guardant Health in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 target price on the stock. Piper Sandler upped their price objective on Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Morgan Stanley raised their target price on Guardant Health from $42.00 to $52.00 and gave the company an “overweight” rating in a research report on Thursday, March 6th. JPMorgan Chase & Co. boosted their price target on shares of Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Finally, Stifel Nicolaus raised their price objective on shares of Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Twenty investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $48.95.

Guardant Health Trading Down 1.5 %

NASDAQ GH opened at $45.15 on Wednesday. The business has a fifty day simple moving average of $44.53 and a 200 day simple moving average of $34.11. Guardant Health has a 12 month low of $15.81 and a 12 month high of $50.89. The firm has a market capitalization of $5.57 billion, a P/E ratio of -12.68 and a beta of 1.50.

Guardant Health (NASDAQ:GH) last announced its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $201.81 million during the quarter, compared to analysts’ expectations of $192.50 million. As a group, sell-side analysts predict that Guardant Health will post -2.9 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC grew its position in shares of Guardant Health by 13.5% during the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock valued at $59,000 after purchasing an additional 230 shares in the last quarter. Summit Investment Advisors Inc. boosted its stake in Guardant Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company’s stock valued at $377,000 after buying an additional 391 shares during the period. Arizona State Retirement System grew its position in Guardant Health by 1.1% during the fourth quarter. Arizona State Retirement System now owns 35,639 shares of the company’s stock worth $1,089,000 after buying an additional 403 shares in the last quarter. Jones Financial Companies Lllp increased its stake in Guardant Health by 43.5% in the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock worth $82,000 after acquiring an additional 817 shares during the last quarter. Finally, Fiduciary Alliance LLC raised its holdings in shares of Guardant Health by 7.6% in the 4th quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company’s stock valued at $363,000 after acquiring an additional 836 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.